| abstract |
FIELD: medicine. n SUBSTANCE: pharmaceutical compositions according to the invention contain at least one dopamine agonist, and a pharmaceutical vehicle comprising a pharmaceutically acceptable permeation enhancer, a pharmaceutically acceptable solubility enhancer, and a pharmaceutically acceptable bioadhesion enhancer. The dosage forms according to the invention have a pharmacological profile, which is described by T max to approximately 90 minutes after administering the dosage form, and the plasma medicament concentration of at least 50% C max over the period of time from 90 to 360 minutes after achieving C max . n EFFECT: improved therapeutic effect as compared to the oral dosage forms of dopamine agonists. n 65 cl, 8 dwg, 29 ex |